<DOC>
	<DOCNO>NCT01363024</DOCNO>
	<brief_summary>This multicenter , open-label , dose-escalation study ass safety , tolerability Pharmacokinetics MGFR1877S .</brief_summary>
	<brief_title>Trial Evaluating Safety Pharmacokinetics MFGR1877S Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Life expectancy &gt; /= 12 week ECOG performance status 0 1 Histologic cytologic documentation locally advance , metastatic solid malignancy relapse failed respond least one prior regimen standard therapy Evaluable measurable disease . Prostate cancer patient nonmeasurable disease eligible two rise prostatespecific antigen ( PSA ) level ( 5 ng/mL measure 2 week apart ) meet PSA Working Group criteria progression prior initiation study treatment . Ovarian cancer patient nonmeasurable disease eligible two rise CA125 level great ULN ( 2 week apart prior initiation study treatment ) . Adequate hematologic end organ function For female patient childbearing potential male patient partner childbearing potential , agreement ( patient and/or partner ) use effective form contraception continue use 90 day last dose study treatment Consent provide archival tissue Prior use monoclonal antibody within 4 week Cycle 1 , Day 1 Experimental therapy within 4 week prior Cycle 1 , Day 1 Palliative radiotherapy within 2 week prior Cycle 1 , Day 1 Prior anticancer therapy within 4 week prior Cycle 1 , Day 1 Major surgical procedure trauma within 4 week prior Cycle 1 , Day 1 . All wound must fully heal Cycle 1 , Day 1 . Evidence significant , uncontrolled concomitant disease could affect compliance protocol interpretation result , include significant cardiovascular disease pulmonary disease Known active bacterial , viral , fungal , mycobacterial , parasitic , infection ( exclude fungal infection nail bed ) screen major episode infection require treatment IV antibiotic hospitalization ( relate completion course antibiotic ) within 4 week prior Cycle 1 , Day 1 History malignancy could affect compliance protocol interpretation result . Patients history curatively treat basal squamous cell carcinoma skin situ carcinoma cervix allow . Patients malignancy treat curative intent also allow malignancy remission without treatment &gt; /= year prior Cycle 1 , Day 1 . Presence positive test result Hepatitis B ( Hepatitis B surface antigen [ HBsAg ] and/or total HB core antibody [ antiHBc ] ) Hepatitis C ( Hepatitis C virus [ HCV ] antibody serology test ) . Patients positive antiHBc eligible PCR negative HBV DNA . Known history HIV seropositive status Primary CNS malignancy , untreated/active CNS metastasis Pregnancy , lactation breastfeed Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render patient high risk treatment complication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Solid Cancers</keyword>
</DOC>